Be aware of SARS-CoV-2 spike protein: There is more than meets the eye.

IF 0.8 4区 医学 Q4 ENDOCRINOLOGY & METABOLISM Journal of biological regulators and homeostatic agents Pub Date : 2021-05-01 DOI:10.23812/THEO_EDIT_3_21
T C Theoharides, P Conti
{"title":"Be aware of SARS-CoV-2 spike protein: There is more than meets the eye.","authors":"T C Theoharides,&nbsp;P Conti","doi":"10.23812/THEO_EDIT_3_21","DOIUrl":null,"url":null,"abstract":"<p><p>The COVID-19 pandemic necessitated the rapid production of vaccines aimed at the production of neutralizing antibodies against the COVID-19 spike protein required for the corona virus binding to target cells. The best well-known vaccines have utilized either mRNA or an adenovirus vector to direct human cells to produce the spike protein against which the body produces mostly neutralizing antibodies. However, recent reports have raised some skepticism as to the biologic actions of the spike protein and the types of antibodies produced. One paper reported that certain antibodies in the blood of infected patients appear to change the shape of the spike protein so as to make it more likely to bind to cells, while other papers showed that the spike protein by itself (without being part of the corona virus) can damage endothelial cells and disrupt the blood-brain barrier. These findings may be even more relevant to the pathogenesis of long-COVID syndrome that may affect as many as 50% of those infected with SARS-CoV-2. In COVID-19, a response to oxidative stress is required by increasing anti-oxidant enzymes. In this regard, it is known that polyphenols are natural anti-oxidants with multiple health effects. Hence, there are even more reasons to intervene with the use of anti-oxidant compounds, such as luteolin, in addition to available vaccines and anti-inflammatory drugs to prevent the harmful actions of the spike protein.</p>","PeriodicalId":15084,"journal":{"name":"Journal of biological regulators and homeostatic agents","volume":"35 3","pages":"833-838"},"PeriodicalIF":0.8000,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"19","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of biological regulators and homeostatic agents","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.23812/THEO_EDIT_3_21","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 19

Abstract

The COVID-19 pandemic necessitated the rapid production of vaccines aimed at the production of neutralizing antibodies against the COVID-19 spike protein required for the corona virus binding to target cells. The best well-known vaccines have utilized either mRNA or an adenovirus vector to direct human cells to produce the spike protein against which the body produces mostly neutralizing antibodies. However, recent reports have raised some skepticism as to the biologic actions of the spike protein and the types of antibodies produced. One paper reported that certain antibodies in the blood of infected patients appear to change the shape of the spike protein so as to make it more likely to bind to cells, while other papers showed that the spike protein by itself (without being part of the corona virus) can damage endothelial cells and disrupt the blood-brain barrier. These findings may be even more relevant to the pathogenesis of long-COVID syndrome that may affect as many as 50% of those infected with SARS-CoV-2. In COVID-19, a response to oxidative stress is required by increasing anti-oxidant enzymes. In this regard, it is known that polyphenols are natural anti-oxidants with multiple health effects. Hence, there are even more reasons to intervene with the use of anti-oxidant compounds, such as luteolin, in addition to available vaccines and anti-inflammatory drugs to prevent the harmful actions of the spike protein.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
注意SARS-CoV-2刺突蛋白:它不仅仅是我们看到的。
COVID-19大流行需要快速生产疫苗,目的是产生针对COVID-19刺突蛋白的中和抗体,这是冠状病毒与靶细胞结合所必需的。最著名的疫苗是利用信使rna或腺病毒载体指导人体细胞产生刺突蛋白,人体对刺突蛋白产生大部分中和抗体。然而,最近的报道对刺突蛋白的生物作用和产生的抗体类型提出了一些怀疑。一篇论文报道,感染患者血液中的某些抗体似乎改变了刺突蛋白的形状,使其更容易与细胞结合,而其他论文则表明,刺突蛋白本身(不是冠状病毒的一部分)可以损害内皮细胞并破坏血脑屏障。这些发现可能与长冠状病毒综合征的发病机制更相关,长冠状病毒综合征可能影响多达50%的SARS-CoV-2感染者。在COVID-19中,需要通过增加抗氧化酶来应对氧化应激。在这方面,众所周知,多酚是具有多种健康作用的天然抗氧化剂。因此,除了可用的疫苗和抗炎药物外,还有更多的理由使用抗氧化化合物(如木犀草素)进行干预,以防止刺突蛋白的有害作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.20
自引率
15.60%
发文量
0
审稿时长
6 months
期刊介绍: Journal of Biological Regulators & Homeostatic Agents (IF 1.397) is a peer-reviewed journal published every 2 months. The journal publishes original papers describing research in the fields of experimental and clinical medicine, molecular biology, biochemistry, regulatory molecules, cellular immunology and pharmacology.
期刊最新文献
Targeted regulation of BBOX1-AS1 on miR-361-3p and its effect on the biological function of non-small cell lung cancer cell. Plasma brain natriuretic peptide levels in children with idiopathic epilepsy treated with longterm sodium valproate and oxcarbazepine monotherapy. Silenced fatty acid-binding protein 4 suppresses epithelial-mesenchymal transition of endometriosis via the phosphatidyl inositol 3-kinase/protein kinase B axis. Analysis of long non-coding RNA expression profiles in disuse osteoporosis using microarray and bioinformatics. Identification of miRNAs, mRNAs, lncRNAs, and circRNAs associated with hepatocellular carcinoma recurrence after interferon treatment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1